Michael Horsman

Professor

Aarhus University
Country flagDenmark

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Year:

2026

A fundamental goal of cancer research is to translate preclinical findings into advances in clinical disease management. In preclinical investigations of anticancer therapeutics, the choices of the model, assay, and endpoint selected are critical in this process. If the model or assay is poorly chosen or the data inappropriately analyzed, preclinical findings can lead to inadequate conclusions that can negatively affect the ability to translate findings from the laboratory to the clinic. The present review discusses the pros and cons of preclinical models, assays, and endpoints commonly used in cancer therapeutic assessment evaluations.

Year:

2026

Background: Re-irradiation is an essential treatment option for recurrent tumours but is limited by normal tissue tolerance. Hyperthermia can enhance radiation efficacy by impairing DNA repair and improving tumor oxygenation; however, limited preclinical data are evaluating its combination with re-irradiation in recurrent tumor settings and normal skin. Objective: The study aims to determine optimal priming doses for skin and tumor response and evaluate the radiosensitising effect of hyperthermia when combined with re-irradiation in preclinical models. Methods: The right rear foot of non-tumor-bearing CDF1 mice or a C3H mammary carcinoma implanted in the foot were treated with a single radiation dose or reirradiation + hyperthermia (42.5°C, 1-h). Initial experiments identified a priming dose of 30 Gy that induced moderate but reversible acute skin toxicity and a tumor dose of 40 Gy that resulted in full regression with regrowth in 30–35 days from treatment. Reirradiation dose–response studies were conducted to determine the MDD₅₀ (skin) and TCD₅₀ (tumor) with and without hyperthermia. Thermal Enhancement Ratios (TER) and Therapeutic Gain Factor (TGF) were calculated. Results: The MDD₅₀ for reirradiation-induced skin damage was 25 Gy, reduced to 18 Gy with hyperthermia (TER = 1.4). In tumours, the TCD₅₀ decreased from 49 Gy (reirradiation alone) to 29 Gy with hyperthermia (TER = 1.7). A TGF of 1.2 was observed, indicating selective enhancement of tumor response relative to skin toxicity. Conclusion: Hyperthermia enhances the therapeutic effect of reirradiation by improving tumor control at lower doses, supporting its potential in recurrent cancer treatment strategies.

Year:

2025

Introduction: There is limited indication of how hyperthermia would influence the unique proposition of FLASH radiation – its ability to maintain comparable tumor response while offering protection to normal tissues. Hence, this study was designed to investigate the potential of combining FLASH radiation with hyperthermia. Materials and methods: Experiments were performed using female CDF1 mice, where the tumor bearing or non-tumor bearing right hind legs were irradiated with either conventional dose rate (CONV) or FLASH radiation ± hyperthermia. Hyperthermia was applied 30 minutes after radiation at 42.5°C for 60 minutes. The tumor endpoint was growth delay to three times its initial treatment volume (TGT3) and the normal tissue endpoint was an acute skin toxicity of score 2.5 and above, characterized by moderate moist desquamation and partial leg deformity. Results: In tumor studies, the thermal enhancement ratio (TER) was 1.68 for FLASH radiotherapy and 1.50 for conventional (CONV) radiation. In acute skin toxicity studies, the TER was slightly lower, at 1.37 for FLASH and 1.29 for CONV. The dose modifying factor (DMF) in tumor studies was 1.12 but decreased to 1.00 when hyperthermia was added. Similarly, in acute skin toxicity studies, the DMF was initially 1.53 and dropped to 1.45 with the addition of hyperthermia. Interpretation: Hyperthermia significantly sensitized both the CONV and FLASH radiation, but the enhancement is comparable between the two different dose rate radiations in both tumors and normal tissues.

Year:

2025

The conventional radiation treatment of cancer patients has typically involved a large number of daily treatments with relatively low doses of radiation. However, improved technology has now resulted in the increased use of fewer radiation fractions at a high dose per fraction. This latter approach is often referred to as hypofractionated irradiation. While conventional radiation typically kills tumor cells through the production of DNA damage, treatments with higher doses per fraction have been suggested to also kill cells via the induction of vascular damage. Such vascular effects will also increase the level of adverse microenvironmental conditions, such as hypoxia and acidity, that already exist in tumors. Cells existing in these adverse microenvironmental conditions are resistant to radiation but actually sensitive to hyperthermia (heating at 40–45 °C) treatment. This suggests that the combination of hypofractionated radiation and heat may be a viable treatment approach. While there are preliminary pre-clinical and even clinical studies investigating this option, there are actually no data on the optimal application for the greatest therapeutic benefit. In this critical review, we will present the rationale for combining hypofractionated radiation with hyperthermia and discuss what has been done and what should be done to establish this combination as an effective cancer therapy option.

Year:

2024

This study investigated the effect of combining radiation with an angiogenesis inhibitor and vascular disrupting agent on tumor response and systemic toxicity. CDF1 mice with 200 mm3 foot implanted C3H mammary carcinomas were treated with TNP-470 (100 mg/kg every second day for 2 weeks; s.c.) and combretastatin A-4 phosphate (CA4P; 1 × 250 mg/kg, i.p.). Radiation (230-kV X-rays) was locally administered to tumors of restrained non-anesthetized mice. Response was tumor growth delay and change in mouse body weight. Radiation induced changes in serum levels of 10 cytokines up to 72-h after irradiation were measured using a Luminex assay. The results showed that TNP-470 (100 mg/kg × 7) or CA4P (250 mg/kg × 1) significantly (Student’s t-test; p < 0.05) inhibited tumor growth; the greatest effect when these two drugs were combined. TNP-470 and CA4P, alone or together, also significantly enhanced tumor response to radiation. No systemic toxicity occurred with drugs administered alone or in combination, but toxicity was observed when TNP-470 was combined with radiation. Serum cytokine levels only showed a significant transient increase in IL-6 1-h after irradiating. In conclusion, combining different acting vascular targeting agents with radiation increased anti-tumor activity. However, this benefit may sometimes be associated with a radiation-induced inflammatory response increasing systemic toxicity.

Year:

2024

This pre-clinical study was designed to demonstrate how vascular disrupting agents (VDAs) should be administered, either alone or when combined with radiation in clinically relevant fractionated radiation schedules, for the optimal anti-tumor effect. CDF1 mice, implanted in the right rear foot with a 200 mm3 murine C3H mammary carcinoma, were injected with various doses of the most potent VDA drug, combretastatin A-1 phosphate (CA1P), under different schedules. Tumors were also locally irradiated with single-dose, or stereotactic (3 × 5–20 Gy) or conventional (30 × 2 Gy) fractionation schedules. Tumor growth and control were the endpoints used. Untreated tumors had a tumor growth time (TGT5; time to grow to 5 times the original treatment volume) of around 6 days. This increased with increasing drug doses (5–100 mg/kg). However, with single-drug treatments, the maximum TGT5 was only 10 days, yet this increased to 19 days when injecting the drug on a weekly basis or as three treatments in one week. CA1P enhanced radiation response regardless of the schedule or interval between the VDA and radiation. There was a dose-dependent increase in radiation response when the combined with a single, stereotactic, or conventional fractionated irradiation, but these enhancements plateaued at around a drug dose of 25 mg/kg. This pre-clinical study demonstrated how VDAs should be combined with clinically applicable fractionated radiation schedules for the optimal anti-tumor effect, thus suggesting the necessary pre-clinical testing required to ultimately establish VDAs in clinical practice.

Year:

2024

Collaborators (9)

Mikkel Holm Vendelbo

VIP, Associate Professor

Aarhus University

DENMARK
View details

Niels Bassler

VIP, Professor

Aarhus University

DENMARK
View details

L. Hoffmann

VIP, Associate Professor

Aarhus University Hospital

DENMARK
View details

Priyanshu Manojkumar Sinha

Aarhus University

DENMARK
View details

Lars Thrane

Aarhus University

DENMARK
View details

Michael Pedersen

VIP, Professor

Aarhus University

DENMARK
View details

Per Rugaard Poulsen

Professor

Aarhus University

DENMARK
View details

Brita Singers Sørensen

VIP, Professor

Aarhus University

DENMARK
View details

Dietmar Siemann

Professor

University of Florida

UNITED STATES
View details